> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Imfinzi/Imjudo OK’d for Lung Cancer
- URL: https://www.fdaweb.com/imfinzi-imjudo-okd-for-lung-cancer/
- Published: 2022-11-11T12:00:00.000Z
- Updated: 2026-09-14T18:06:07.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5153186

FDA has approved AstraZeneca’s Imfinzi (durvalumab) in combination with Imjudo (tremelimumab) plus platinum-based chemotherapy for treating adult patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC). The approval was based on data from the [POSEIDON Phase 3 trial](https://www.astrazeneca.com/media-centre/press-releases/2021/imfinzi-improves-survival-in-nsclc-in-poseidon.html?ref=fdaweb.com), which showed that patients treated with the combination saw a 23% reduction in the risk of death versus a range of chemotherapy options, the company says. “An estimated 33% of patients were alive at two years versus 22% for chemotherapy.”

Imfinzi is described as a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, “countering the tumor’s immune-evading tactics and releasing the inhibition of immune responses,” AstraZeneca says. It is currently approved for use in lung cancer, biliary tract cancer and hepatocellular carcinoma.

Imjudo is a human monoclonal antibody that targets the activity of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), according to the company, adding that the therapy blocks the activity of CTLA-4, “contributing to T-cell activation, priming the immune response to cancer and fostering cancer cell death.”